Works cited by this work

91 works

Work: Serum tyrosine associates with increased CSF Aβ42, reduced Aβ deposition, and cognitive improvement in MCI: modulation by confounding factors

1. Comprehensive and Neuropsychologic Evaluations

   Richard C. Mohs

   Review article19964 citations

   ABIABI:AkademIndex/openalex/2026.other.775807

2. Escala de Avaliação da Doença de Alzheimer - Subescala Cognitiva (ADAS-Cog): Dados Normativos para a População Portuguesa

   Joana Nogueira, Sandra Freitas, Diana Duro +4

   Article20184 citations

   ABIABI:AkademIndex/openalex/2026.other.775825

3. The duality of amyloid-β: its role in normal and Alzheimer’s disease states

   Ali Azargoonjahromi

   Review article20244 citations

   ABIABI:AkademIndex/openalex/2026.other.775861

4. Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

   Donovan McGrowder, Fabian Miller, Kurt Vaz +9

   Review article20213 citations

   ABIABI:AkademIndex/openalex/2026.other.292518

5. CSF Amyloid-β42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism

   Ali Azargoonjahromi, Hamide Nasiri, for the Alzheimer’s Disease Neuroimaging Initiative#

   Article20253 citations

   ABIABI:AkademIndex/openalex/2026.other.775873

6. ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

   Takahisa Kanekiyo, Huaxi Xu, Guojun Bu

   Review article20142 citations

   ABIABI:AkademIndex/openalex/2026.other.292451

7. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies

   Ana‐Caroline Raulin, Sydney V. Doss, Zachary A. Trottier +3

   Review article20222 citations

   ABIABI:AkademIndex/openalex/2026.other.339258

8. A central role for dityrosine crosslinking of Amyloid-β in Alzheimer’s disease

   Youssra K. Al‐Hilaly, Thomas L. Williams, Maris Stewart-Parker +8

   Article20132 citations

   ABIABI:AkademIndex/openalex/2026.other.744555

9. CSF biomarkers for Alzheimer's disease: current utility and potential future use

   David M. Holtzman

   Article20112 citations

   ABIABI:AkademIndex/openalex/2026.other.775788

10. Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

    Ruth Motter, Carmen Vigo‐Pelfrey, Dora Kholodenko +14

    Article19952 citations

    ABIABI:AkademIndex/openalex/2026.other.775789

11. <scp>CSF</scp> A<i>β</i>42/A<i>β</i>40 and A<i>β</i>42/A<i>β</i>38 ratios: better diagnostic markers of Alzheimer disease

    Shorena Janelidze, Henrik Zetterberg, Niklas Mattsson +9

    Article20162 citations

    ABIABI:AkademIndex/openalex/2026.other.775815

12. Immunotherapy in Alzheimer’s disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline

    Ali Azargoonjahromi

    Review article20242 citations

    ABIABI:AkademIndex/openalex/2026.other.775860

13. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775787

14. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775790

15. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775791

16. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775792

17. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775793

18. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775794

19. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775795

20. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775796

21. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775797

22. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775798

23. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775799

24. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775800

25. Untitled

    Other1 citations

    ABIABI:AkademIndex/openalex/2026.other.775801